Plain-English translation of NCT05209620 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether orelabrutinib, combined with a chemotherapy drug called , can help people whose brain lymphoma has come back or is no longer responding to prior treatment. The trial will watch how well this medication combination works and what side effects people experience. About 30 people will participate.
Brain lymphoma that returns after treatment or doesn't respond to initial therapy is very difficult to treat, and doctors need new options. This trial is testing whether this medication combination might offer patients a better chance at controlling their disease.
You likely qualify if…
You likely don't qualify if…
You will take orelabrutinib as a daily oral medication (a pill by mouth). Every 3 weeks, you will also receive an intravenous infusion of at the hospital or clinic on day 5 of each cycle. This induction phase lasts for 6 cycles (about 18 weeks), after which you will continue taking orelabrutinib daily as maintenance treatment. Your doctor will monitor you regularly with blood tests and imaging scans to track how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Henan Cancer Hospital
Enrollment target
~30 participants
Started
December 2021
Primary completion
June 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhihua Yao, M.D. Ph.D
Henan Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.